An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Clinical trial NCT00492986 · COMPLETED

Trial details

NCT number: NCT00492986
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2005-10-01
Primary completion: 2008-11-01
Enrollment: 1150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.